Jeffrey Steven Sloan
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Corpay Faces Earnings Watch Amid Volatus Aerospace Deal. Investors are closely watching Corpay as it prepares for its next earnings report, with analysts debating if it will continue to beat estimates. Separately, a $13 million deal between Volatus Aerospace and AISPECO was announced, adding to the corporate activity surrounding the company. The stock currently trades with a trailing P/E of 22.9, while the average analyst price target stands at $461.00.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Guidewire Shares Rise as West Bend Expands AI Claims Platform. Guidewire Software shares climbed alongside other software peers, supported by news that West Bend is building an AI-driven claims foundation on the company's platform. This development highlights ongoing adoption of Guidewire's technology in insurance operations. The stock remains well below its 52-week high, with analysts maintaining a higher average price target.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BofA reinstates Global Payments coverage with $114 target. Bank of America has restarted coverage on Global Payments, issuing a buy rating and a price target of $114. This move places the stock within a broader wave of analyst actions affecting the payments sector, which also saw updates for FIS and Toast. The new target sits above the current average analyst estimate of $105.34, signaling renewed institutional interest in the company's outlook.
Transaction History
| VYX | ▲ Buy | Grant | 26,573 | $0 | 6/3/2026 | View on chart |
| CPAY | ▲ Buy | Grant | 886 | $0 | 2/24/2026 | View on chart |
| CPAY | ▼ Sell | Open Market | 3,600 | $1.2M | 2/17/2026 | View on chart |
| GWRE | ▲ Buy | Grant | 1,196 | $0 | 12/15/2025 | View on chart |
| VYX | ▲ Buy | Grant | 14,096 | $0 | 6/6/2025 | View on chart |
| VYX | ▲ Buy | Grant | 3,712 | $0 | 3/3/2025 | View on chart |
| CPAY | ▲ Buy | Grant | 796 | $0 | 2/14/2025 | View on chart |
| GWRE | ▲ Buy | Grant | 1,175 | $0 | 1/21/2025 | View on chart |
| CPAY | ▲ Buy | Grant | 1,102 | $300K | 2/14/2024 | View on chart |
| GPN | ▲ Buy | Grant | 27,113 | $3.0M | 2/24/2023 | View on chart |
| GPN | ▼ Sell | Tax Withholding | 14,760 | $1.7M | 2/24/2023 | View on chart |
| GPN | ▼ Sell | Tax Withholding | 15,596 | $1.8M | 2/22/2023 | View on chart |
| GPN | ▲ Buy | Grant | 41,991 | $4.8M | 2/21/2023 | View on chart |
| CPAY | ▲ Buy | Grant | 1,497 | $0 | 1/23/2023 | View on chart |
| GPN | ▲ Buy | Grant | 42,896 | $5.9M | 2/25/2022 | View on chart |
| GPN | ▼ Sell | Tax Withholding | 22,572 | $3.1M | 2/25/2022 | View on chart |
| GPN | ▼ Sell | Tax Withholding | 2,532 | $343K | 2/24/2022 | View on chart |
| GPN | ▲ Buy | Grant | 27,200 | $3.7M | 2/22/2022 | View on chart |
| GPN | ▼ Sell | Tax Withholding | 6,866 | $934K | 2/22/2022 | View on chart |
| GPN | ▲ Buy | Grant | 12,866 | $1.8M | 2/22/2022 | View on chart |
| GPN | ▲ Buy | Grant | 26,651 | $3.6M | 2/22/2022 | View on chart |
| CPAY | ▲ Buy | Grant | 1,331 | $0 | 1/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Goldman Sachs cuts NCR Voyix price target to $8
Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.
Goldman Sachs cuts NCR Voyix price target to $8. Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.